Table 1: Characteristics of landmark studies included in the systematic review and meta-analysis evaluating the prognostic and therapeutic implications of the WHO 2021 molecular classification of adult diffuse gliomas. Studies shown represent major randomized trials and molecular cohort investigations that substantially contributed to the evidence base supporting integrated molecular diagnosis and prognostic stratification. Most studies reported outcomes according to molecular biomarkers incorporated within the WHO 2021 classification framework, including IDH mutation status, 1p/19q codeletion, CDKN2A/B homozygous deletion, MGMT promoter methylation, TERT promoter mutation, EGFR amplification, and chromosome +7/-10 alterations.

Study

Year

Country

Study Design

Sample Size (n)

Molecular Marker

Median Follow-up (months)

Eckel-Passow, et al.

2015

USA

Retrospective Cohort

1087

IDH, 1p/19q, TERT

74

Ceccarelli, et al.

2016

International

Genomic Cohort

1122

Multi-marker

68

Buckner, et al. (RTOG 9802)

2016

USA

RCT

251

IDH, 1p/19q

11.9 years

Cairncross et al. (RTOG 9402)

2013

USA

RCT

291

1p/19q

16 years

Van den Bent, et al. (EORTC 26951)

2013

Europe

RCT

368

1p/19q

12 years

Van den Bent, et al. (CATNON)

2021

International

RCT

751

IDH

55

Shirahata, et al.

2018

Germany

Retrospective Cohort

824

CDKN2A/B

63

Johnson, et al.

2014

USA

Genomic Cohort

114

IDH

48

TCGA Consortium

2015

International

Genomic Database

293

Multi-marker

60

Weller, et al.

2021

Europe

Prospective Cohort

547

WHO 2021 markers

50